These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 17922920)

  • 1. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.
    van de Vijver M; Bilous M; Hanna W; Hofmann M; Kristel P; Penault-Llorca F; Rüschoff J
    Breast Cancer Res; 2007; 9(5):R68. PubMed ID: 17922920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M; Morey A; Armes J; Cummings M; Francis G
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
    Riethdorf S; Hoegel B; John B; Ott G; Fritz P; Thon S; Loening T; Pantel K
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):261-9. PubMed ID: 20396915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
    Wixom CR; Albers EA; Weidner N
    Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):248-51. PubMed ID: 15551739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
    Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
    Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
    Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
    Shen DH; Wang FH; Yu YZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma.
    Dandachi N; Dietze O; Hauser-Kronberger C
    Lab Invest; 2002 Aug; 82(8):1007-14. PubMed ID: 12177239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer.
    Arnould L; Denoux Y; MacGrogan G; Penault-Llorca F; Fiche M; Treilleux I; Mathieu MC; Vincent-Salomon A; Vilain MO; Couturier J
    Br J Cancer; 2003 May; 88(10):1587-91. PubMed ID: 12771927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization.
    Loring P; Cummins R; O'Grady A; Kay EW
    Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):194-200. PubMed ID: 15894935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.
    Hauser-Kronberger C; Dandachi N
    J Mol Histol; 2004 Aug; 35(6):647-53. PubMed ID: 15614619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
    Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogenic
    Ali AHM; Yahya AQ; Mohammed HL
    Open Access Maced J Med Sci; 2019 Jun; 7(12):1917-1925. PubMed ID: 31406529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.
    Li-Ning-T E; Ronchetti R; Torres-Cabala C; Merino MJ
    Int J Surg Pathol; 2005 Oct; 13(4):343-51. PubMed ID: 16273190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification.
    Cayre A; Mishellany F; Lagarde N; Penault-Llorca F
    Breast Cancer Res; 2007; 9(5):R64. PubMed ID: 17908324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm.
    Hanna WM; Kwok K
    Mod Pathol; 2006 Apr; 19(4):481-7. PubMed ID: 16444193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization.
    Moelans CB; de Weger RA; van Blokland MT; Ezendam C; Elshof S; Tilanus MG; van Diest PJ
    Cell Oncol; 2009; 31(1):1-10. PubMed ID: 19096145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
    Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
    J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.